| Comment type | Description |
|---|
| Alternative Products | Event=Alternative splicing; Named isoforms=3; Comment=Additional isoforms seem to exist.; Name=2; IsoId=P37231-1; Sequence=Displayed; Name=1; Synonyms=PPARgamma1(wt); IsoId=P37231-2; Sequence=VSP_003645; Name=3; Synonyms=PPARgamma1(tr); IsoId=P37231-3; Sequence=VSP_003645, VSP_043906, VSP_043907; Note=Exhibits dominant negative activity over isoform 1.; |
| Disease | Glioma 1 (GLM1) [MIM |
| Disease | Lipodystrophy, familial partial, 3 (FPLD3) [MIM |
| Disease | Note=Defects in PPARG can lead to type 2 insulin- resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. |
| Disease | Obesity (OBESITY) [MIM |
| Enzyme Regulation | PDPK1 activates its transcriptional activity independently of its kinase activity. |
| Function | Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. {ECO |
| Interaction | Q00535:CDK5; NbExp=2; IntAct=EBI-781416, EBI-1041567; P10909:CLU; NbExp=3; IntAct=EBI-781384, EBI-1104674; O60869:EDF1; NbExp=4; IntAct=EBI-781384, EBI-781301; P42858:HTT; NbExp=4; IntAct=EBI-781384, EBI-466029; Q6STE5-1:SMARCD3; NbExp=3; IntAct=EBI-781384, EBI-488506; Q6STE5-2:SMARCD3; NbExp=3; IntAct=EBI-781384, EBI-488511; |
| Polymorphism | Genetic variation in PPARG may influence body mass index (BMI) [MIM |
| Polymorphism | Genetic variations in PPARG influence the carotid intimal medial thickness (CIMT) [MIM |
| Ptm | O-GlcNAcylation at Thr-84 reduces transcriptional activity in adipocytes. |
| Ptm | Phosphorylated in basal conditions and dephosphorylated when treated with the ligand. May be dephosphorylated by PPP5C. The phosphorylated form may be inactive and dephosphorylation at Ser- 112 induces adipogenic activity (By similarity). |
| Sequence Caution | Sequence=AAN38992.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence= ; Sequence=BAA23354.1; Type=Erroneous gene model prediction; Evidence= ; Sequence=BAF83270.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence= ; Sequence=CAA62153.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence= ; |
| Similarity | Belongs to the nuclear hormone receptor family. NR1 subfamily. |
| Similarity | Contains 1 nuclear receptor DNA-binding domain. |
| Subcellular Location | Nucleus. Cytoplasm. Note=Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. CCRN4L/NOC enhances its nuclear translocation. |
| Subunit | Interacts with FOXO1 (acetylated form) (By similarity). Heterodimer with other nuclear receptors, such as RXRA. The heterodimer with the retinoic acid receptor RXRA is called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 and NCOA2 LXXLL motifs. Interacts with ASXL1, ASXL2, DNTTIP2, FAM120B, MAP2K1/MEK1, NR0B2, PDPK1, PRDM16, PRMT2 and TGFB1I1. Interacts (when activated by agonist) with PPP5C. Interacts with HELZ2 and THRAP3; the interaction stimulates the transcriptional activity of PPARG. Interacts with PER2, the interaction is ligand dependent and blocks PPARG recruitment to target promoters. Interacts with CCRN4L/NOC. {ECO |
| Tissue Specificity | Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary. |
| Web Resource | Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/PPARGID383ch3p25.html"; |
| Web Resource | Name=SeattleSNPs; URL="http://pga.gs.washington.edu/data/pparg/"; |
| Web Resource | Name=SHMPD; Note=The Singapore human mutation and polymorphism database; URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=PPARG"; |
| Web Resource | Name=Wikipedia; Note=Peroxisome proliferator- activated receptor entry; URL="http://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor"; |